Press release



Information on the Annual Financial Statements


Paris (France) and Cambridge (Massachusetts, USA), June 30, 2025 – 10:30 PM (CET) – Biophytis SA
(Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company
specializing in developing treatments for age-related diseases announces that it is not in a position to
publish its 2024 annual accounts on the previously scheduled date.

Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest.




About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-
related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in
development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity,
Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge,
Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS
- FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US
09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all
statements that are not historical facts. In some cases, you can identify these forward-looking statements
by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the
negative version of these words or other comparable words. Such forward-looking statements are based
on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the
statements contained in such forward-looking statements will be verified, which are subject to various risks
and uncertainties. The forward- looking statements contained in this press release are also subject to risks
not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will
be important factors that could cause actual outcomes or results to differ materially from those indicated
in these statements.



Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023
Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors"
section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA).
We undertake no obligation to publicly update or review any forward-looking statement, whether because
of new information or otherwise, except as required by law.


Page 1 sur 2
Press release

Biophytis Contacts
Investor Relations
Investors@biophytis.com

US Investors
Pascal Nigen – Alpha Bronze
pnigen@alphabronzellc.com

Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78




Page 2 sur 2